Showing 281 - 300 results of 12,614 for search '"drug"', query time: 0.07s Refine Results
  1. 281
  2. 282

    A Challenge for Diagnosing Acute Liver Injury with Concomitant/Sequential Exposure to Multiple Drugs: Can Causality Assessment Scales Be Utilized to Identify the Offending Drug? by Roxanne Lim, Hassan Choudry, Kim Conner, Wikrom Karnsakul

    Published 2014-01-01
    “…Drug-induced hepatotoxicity most commonly manifests as an acute hepatitis syndrome and remains the leading cause of drug-induced death/mortality and the primary reason for withdrawal of drugs from the pharmaceutical market. …”
    Get full text
    Article
  3. 283

    Comparative drug-drug interactions of berberine and astragaloside IV in normal and type 2 diabetes mellitus rats based on UPLC-QqQ-MS/MS by Yan Lei, Jiaqi Xie, Zhongshui Xie, Xiaojun Zhao, Jianmei Huang, Can Wang

    Published 2025-01-01
    “…The gut microbiota was enriched in the intestines of T2DM rats and promoted the hydrolysis of AST to produce CAG, while the drug-drug interaction between AST and BBR was blocked.…”
    Get full text
    Article
  4. 284
  5. 285

    Serum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial by Selma Atalay, Sophie E. Berends, Hans M. M. Groenewoud, Ron A. A. Mathot, David M. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. A. Koetsier, Maartje A. Berends, Annick de Vries, Peter C. M. van de Kerkhof, Alfons A. den Broeder, Elke M. G. J. de Jong, Juul M. P. A. van den Reek

    Published 2022-07-01
    “…However, fear for increased anti-drug antibody (ADA) formation due to interval prolongation of biologics is an important barrier.Objective To investigate the course of serum drug concentrations, ADA levels, and predictors for successful dose reduction of adalimumab, ustekinumab, and etanercept for psoriasis.Methods Patients were randomized to dose reduction (DR) or usual care (UC) and followed for one year. …”
    Get full text
    Article
  6. 286
  7. 287
  8. 288
  9. 289
  10. 290
  11. 291
  12. 292
  13. 293

    Eccentric indices based QSPR evaluation of drugs for schizophrenia treatment by Muneeba Mansha, Sarfraz Ahmad, Zahid Raza

    Published 2025-01-01
    “…Creating computational tools to find and develop drugs for schizophrenia has more interest in the past few years. …”
    Get full text
    Article
  14. 294
  15. 295
  16. 296

    Real-World Experience with Dolutegravir-Based Two-Drug Regimens by Douglas Ward, Moti Ramgopal, David J. Riedel, Cindy Garris, Shelly Dhir, John Waller, Jenna Roberts, Katie Mycock, Alan Oglesby, Bonnie Collins, Megan Dominguez, James Pike, Joseph Mrus

    Published 2020-01-01
    “…Background. Dolutegravir-based 2-drug regimens (DTG 2DRs) are now accepted as alternatives to 3-drug regimens for HIV antiretroviral treatment (ART); however, literature on physician drivers for prescribing DTG 2DR is sparse. …”
    Get full text
    Article
  17. 297
  18. 298
  19. 299

    PHARMACEUTICAL TECHNIQUES FOR THE FABRICATION OF POOR WATERSOLUBLE DRUGS A REVIEW by Rabia Noor

    Published 2024-10-01
    “… Pharmaceutical technologies for increasing the solubility of drug substances have a prime role in its faster dissolution and maximum absorption in the systemic circulation. …”
    Get full text
    Article
  20. 300